经公司自查并向控股股东、实际控制人书面发函问询，经回复，公司控 股股东、实际控制人除已披露的关于控股股东签署《股份转让协议》、《股份转 让协议之补充协议》、《关于放弃表决权的承诺函》暨公司控制权拟发生变更的 事项外，公司不存在应披露而未披露的重大事项。具体内容详见公司于 2025 年 3 月 21 日、3 月 26 日在上海证券交易所网站（www.sse.com.cn）披露的 2025-007 号、2025-009 号公告。 公司控制权拟发生变更事项尚需取得上海证券交易所出具协议转让合规 确认意见，并在中国证券登记结算有限责任公司上海分公司办理过户登记手续， 上述事项最终能否实施完成及完成时间尚存在不确定性。敬请广大投资者关注公 司后续公告，注意投资风险。 一、股票交易异常波动的具体情况 公司股票于 2025 年 6 月 9 日、6 月 10 日、6 月 11 日连续三个交易日内收盘 价格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 二、公司关注并核实的相关情况 证券代码：603139 证券简称：康惠制药 公告编号：2025-032 陕西康惠制药股份有限公 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-033 陕西康惠制药股份有限公司 关于持股 5%以上股东协议转让公司部分股份 完成过户登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、股份转让相关事项概述 2025 年 4 月 21 日，陕西康惠制药股份有限公司（以下简称"公司"）持股 5%以上股东上海赛乐仙企业管理咨询有限公司（以下简称"赛乐仙"）与扬州创 响投资合伙企业（有限合伙）（以下简称"创响投资"）签订了《关于陕西康惠 制药股份有限公司之股份转让协议》，赛乐仙拟将其持有的公司无限售条件流通 股 5,992,800 股（占公司总股本的 6%）转让给创响投资。 本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发生变 更 （ 具 体 内 容 详 见 公 司 于 2025 年 4 月 22 日 在 上 海 证 券 交 易 所 网 站 http://www.sse.com.cn 披露的 2025-016 号公告及相关股东披露的《简式权益变动 报告书》）。 二、股份转让进展暨过户情况 本 ...

关于《陕西康惠制药股份有限公司关于股票交易异常波动有关问 题的问询函》的回复 陕西康惠制药股份有限公司: 陕西康惠控股有限公司(以下简称本公司)于 2025年6月11日收到陕西康 惠制药股份有限公司(以下简称贵司或公司)发来的《陕西康惠制药股份有限公 司关于股票交易异常波动有关问题的问询函》,经本公司认真自查,现回复如下: 本公司作为贵司的控股股东,截止目前,除已披露的关于控股股东签署《股 份转让协议》、《股份转让协议之补充协议》、《关于放弃表决权的承诺函》暨公司 控制权拟发生变更的事项外,不存在影响贵司股票交易价格异常波动的重大事宜; 不存在应披露而未披露的重大信息,包括但不限于重大资产重组、发行股份、上 市公司收购、债务重组、业务重组、资产剥离和资产注入等重大事项:不存在股 票异常波动期间买卖公司股票的情况。 特此回复。 (以下无正文,后附签署页) S 扫描全能王 用的扫描 App (本页无正文,为《关于<陕西康惠制药股份有限公司关于股票交易异常波动有 关问题的问询函>的回复》之签署页) 控股股东(盖章):陕西康 2025年6月11日 关于《陕西康惠制药股份有限公司关于股票交易异常波动有关问 题的问询函》 ...

Core Insights - The hair medical concept sector has seen a rise of 2.25%, ranking third among concept sectors in terms of growth [1] - Within this sector, 11 stocks increased in value, with notable performers including Aoyang Health, Kanghui Pharmaceutical, and *ST Meigu, which reached their daily limit [1] - The sector experienced a net inflow of 64 million yuan from main funds, with Aoyang Health leading the inflow at 68.73 million yuan [2][3] Sector Performance - The hair medical concept sector's performance is highlighted by the following stocks: - Aoyang Health: increased by 10.12% with a turnover rate of 26.84% and a net inflow of 68.73 million yuan [3] - Taiankang: increased by 9.35% with a turnover rate of 10.42% and a net inflow of 51.69 million yuan [3] - Kanghui Pharmaceutical: increased by 9.99% with a turnover rate of 4.06% and a net inflow of 33.06 million yuan [3] - Huailong Co.: increased by 3.35% with a turnover rate of 11.07% and a net inflow of 14.87 million yuan [3] Fund Flow Analysis - The top stocks by net inflow ratio in the hair medical sector include: - Kanghui Pharmaceutical: net inflow ratio of 36.67% [3] - *ST Meigu: net inflow ratio of 11.74% [4] - Aoyang Health: net inflow ratio of 7.40% [3] - The overall trend indicates a strong interest from main funds in the hair medical sector, with several stocks showing significant inflows [2][3]

Industry Overview - The hair medical sector has shown significant activity recently, with the sector index reaching a new high as of June 10, 2023, driven by active stock performances from companies like Aoyang Health and Kanghui Medical [1] - The hair medical services can be divided into hair transplant services and medical hair care services, with hair transplant services currently dominating the market [1] - The growing trend of beauty economy and self-consumption is leading consumers to invest more time and money in hair health and aesthetics, which is expected to drive continuous growth in the hair medical industry [1] - According to Frost & Sullivan, the market size of hair medical services in China is projected to reach 138.1 billion yuan by 2030, with a CAGR of 22.3% from 2020 to 2030 [1] Market Dynamics - The medical hair care market is expected to grow rapidly due to the high frequency and repurchase characteristics of hair care services, with the "hair transplant and care" integration trend driving this growth [2] - By 2030, the medical hair care services are anticipated to account for 45.3% of the total hair medical services market in China, becoming a significant driver of industry development [2] Key Companies - Zhendong Pharmaceutical (300158): The company's main product, Dafeixin Minoxidil Solution, is the only topical medication approved by both the FDA and NMPA for treating hair loss [2] - Huilong Co., Ltd. (002556): The company offers hair growth and hair loss treatment products, including Zhi Zhi Hair Growth Tablets and Compound Ginseng Phenol Solution, which have national drug approval [2] - Kanghui Pharmaceutical (603139): The company has several drugs listed in the national medical insurance directory, including hair loss treatment tablets [3] - Aoyang Health: The company's subsidiary, Weien Medical Beauty, includes hair transplant services [4] - Tainkang (301263): The company is applying for a one-time import of raw materials for Baricitinib, which is under research for hair growth indications [4] - Kangyuan Pharmaceutical: The new hair loss treatment drug Minoxidil Tincture has completed registration verification and GMP compliance checks [4] - Langzi Co., Ltd. (002612): The company has medical beauty institutions that offer hair transplant-related services [5] - Huabang Health (002004): The company has a hair transplant center under Maan Skin, utilizing MN-FUE hair transplant technology for patient treatment [6]

暗盘资金一眼洞悉庄家意图>> 牙科医疗板块盘初拉升，皓宸医疗（002622）封板涨停，爱迪特（301580）涨超5%，康惠制药 （603139）、悦心健康（002162）、正海生物（300653）、国瓷材料（300285）等均涨超2%。 ...

Group 1 - The A-share dental medical sector experienced a significant rise at the beginning of trading, with Haocen Medical hitting the daily limit and closing up [1] - Aidi Te rose over 5%, while Kanghui Pharmaceutical, Yueshin Health, Zhenghai Biological, and Guoci Materials all increased by more than 2.5% [1]

Core Viewpoint - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., is set to hold an investor performance briefing on June 13, 2025, to discuss its 2024 annual report and Q1 2025 results, allowing for interactive communication with investors [2][3]. Group 1: Meeting Details - The meeting is scheduled for June 13, 2025, from 11:00 AM to 12:00 PM [3]. - It will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [2][3]. - The format of the meeting will be an online interactive session [2][3]. Group 2: Participation Information - Investors can participate online on June 13, 2025, through the Shanghai Stock Exchange Roadshow Center [4]. - Questions can be submitted from June 6 to June 12, 2025, via the Roadshow Center's website or through the company's email [4][5]. - The company will address commonly asked questions during the briefing [4]. Group 3: Attendees - Key attendees will include the company's Chairman and General Manager, Mr. Wang Yanling, the Board Secretary, Ms. Dong Juan, the Chief Financial Officer, Mr. Zou Binze, and Independent Director, Mr. Kang Yuke [3].

证券代码：603139 证券简称：康惠制药 公告编号：2025-031 陕西康惠制药股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间： 2025 年 6 月 13 日（星期五）上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 3、会议召开方式：上证路演中心网络互动 三、参加人员 公司董事长兼总经理王延岭先生、董事会秘书董娟女士、财务总监邹滨泽先 生、独立董事康玉科先生（如有特殊情况，参会人员将可能进行调整）。 四、投资者参加方式 投资者可于 2025 年 6 月 6 日(星期五)至 6 月 12 日(星期四)16:00 前登 录 上 证 路 演中 心 网 站 首 页 点 击 " 提 问 预 征 集" 栏 目 或 通 过公 司 邮 箱 （irsxkh@ ...

Group 1 - The hair medical concept sector increased by 2.20%, ranking 6th among concept sectors, with 16 stocks rising, including Huailong Co., which hit the daily limit, and Zhendong Pharmaceutical, *ST Meigu, and Baicheng Pharmaceutical showing notable gains of 7.32%, 4.81%, and 3.56% respectively [1][2] - The sector saw a net inflow of 142 million yuan from main funds, with 11 stocks receiving net inflows, led by Huailong Co. with a net inflow of 134 million yuan, followed by Baicheng Pharmaceutical, Shuiyang Co., and Minsheng Health with net inflows of 34.48 million yuan, 18.79 million yuan, and 11.22 million yuan respectively [2][3] - In terms of fund inflow ratios, Huailong Co., Baicheng Pharmaceutical, and International Medicine had the highest net inflow rates of 31.08%, 11.58%, and 6.12% respectively [3] Group 2 - The top gainers in the hair medical concept sector included Huailong Co. with a daily increase of 10.00% and a turnover rate of 7.90%, and Baicheng Pharmaceutical with a 3.56% increase and a turnover rate of 10.97% [3][4] - Conversely, the top decliners included Jiu Zhi Tang, Neng Te Ke Ji, and Kang Hui Pharmaceutical, which fell by 1.06%, 0.62%, and 0.36% respectively [1][4] - The overall performance of the hair medical concept sector reflects a positive trend in investor sentiment and capital inflow, indicating potential growth opportunities within the sector [2][3]